BG Medicine, Inc. Announces Proposed Public Offering of Common Stock
April 02 2014 - 4:05PM
BG Medicine, Inc. (Nasdaq:BGMD), the developer of
the BGM Galectin-3® Test, today announced that it intends to offer
and sell shares of its common stock in an underwritten public
offering. BG Medicine also expects to grant the underwriters a
30-day option to purchase additional shares of common stock to
cover over-allotments, if any. Lazard Capital Markets LLC is acting
as sole book-running manager for the offering. While the offering
is expected to price before 9:30 am EDT on April 3, 2014, the
offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
A registration statement on Form S-3 relating to the common
stock offered in this offering was filed with, and declared
effective by, the Securities and Exchange Commission (the "SEC"). A
preliminary prospectus supplement, as well as a final prospectus
supplement, relating to and describing the terms of the offering
will be filed with the SEC, each of which will form a part of the
effective registration statement. When available, copies of the
preliminary and final prospectus supplements relating to these
securities may be obtained by visiting the SEC's website at
www.sec.gov or from Lazard Capital Markets LLC, 30 Rockefeller
Plaza, 60th Floor, New York, NY 10020 or via telephone at (212)
632-6717.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM
Galectin-3® Test, is focused on the development and delivery of
diagnostic solutions to aid in the clinical management of heart
failure and related disorders. For additional information about BG
Medicine, heart failure and galectin-3 testing, please visit
www.bg-medicine.com.
The BG Medicine Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10352
Forward-Looking Statements
Certain statements made in this news release contain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities and Exchange Act of 1934, as amended, that are intended
to be covered by the "safe harbor" created by those sections.
Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can
generally be identified by the use of forward-looking terms such as
"believe," "expect," "may," "will," "should," "could," "seek,"
"intend," "plan," "estimate," "anticipate" or other comparable
terms. Forward-looking statements in this news release include, but
are not limited to, those regarding BG Medicine's expectations
regarding its fundraising efforts, including its intention to offer
and sell shares of its common stock in an underwritten public
offering, its expectation that it will grant the underwriters an
option to purchase additional shares, and its expectations
regarding the timing of the pricing, the price and the other terms
of the offering. Forward-looking statements are based on
management's current expectations and involve inherent risks and
uncertainties which could cause actual results to differ materially
from those in the forward-looking statements, as a result of
various factors including those risks and uncertainties described
in the Risk Factors and in Management's Discussion and Analysis of
Financial Condition and Results of Operations sections of our
recent filings with the Securities and Exchange Commission,
including a preliminary prospectus supplement filed on April 2,
2014 and our most recent Annual Report on Form 10-K filed on March
27, 2014. We urge you to consider those risks and uncertainties in
evaluating our forward-looking statements. We caution readers not
to place undue reliance upon any such forward-looking statements,
which speak only as of the date made. Except as otherwise required
by the federal securities laws, we disclaim any obligation or
undertaking to publicly release any updates or revisions to any
forward-looking statement contained herein (or elsewhere) to
reflect any change in our expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based.
CONTACT: Stephen P. Hall
EVP & Chief Financial Officer
Tel. (781) 434-0210
BG Medicine (CE) (USOTC:BGMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
BG Medicine (CE) (USOTC:BGMD)
Historical Stock Chart
From Sep 2023 to Sep 2024